Inflammatory and Antioxidant Pattern Unbalance in “Clopidogrel-Resistant” Patients during Acute Coronary Syndrome
Table 3
Redox status at 24 hours from daily administration of dual antiplatelet treatment between clopidogrel responders and nonresponders.
All cases ( = 23)
Responders ( = 17)
Nonresponders ( = 6)
r-Hcypl, μmol/L
0.19 (0.14–0.20)
0.20 (0.15–0.25)
0.17 (0.10–0.19)
0.227
t-Hcypl, μmol/L
13.5 (8.6–15.3)
13.0 (8.6–15.2)
13.9 (9.8–16.6)
0.812
r-GSHpl, μmol/L
3.93 (1.64–5.59)
4.25 (1.54–6.24)
3.52 (1.71–4.50)
0.412
t-GSHpl, μmol/L
6.10 (2.78–7.08)
6.26 (3.46–7.08)
3.84 (2.60–7.46)
0.560
r-GSHbl, μmol/L
426 (393–500)
451 (410–537)
392 (315–431)
0.033
t-GSHbl, μmol/L
998 (784–1099)
1031 (876–1108)
873 (716–1054)
0.294
GPx-1, IU/grHb
12.8 (9.3–17.8)
12.6 (9.3–13.4)
19.5 (8.7–27.5)
0.203
Data are expressed as median and interquartile range (25th–75th). Bl: blood; GSH: glutathione; GPx-1: glutathione peroxidase type-1; GPx-3: glutathione peroxidase type-3; pl: plasma; r: reduced; t: total.
